[Olaparib (prostate cancer) – Addendum to Commission A23-03]

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen

Record ID 32018005112

German

Original Title: Olaparib (Prostatakarzinom) - Addendum zum Projekt A23-03 (Dossierbewertung)

Details

Project Status: Completed

URL for project: https://www.iqwig.de/projekte/a23-47.html

Year Published: 2023

URL for published report: https://www.iqwig.de/download/a23-47_olaparib_addendum-zum-projekt-a23-03_v1-0.pdf

English language abstract: There is no English language summary available

Publication Type: Full HTA

Country: Germany

MeSH Terms

Prostatic Neoplasms
Prostatic Neoplasms, Castration-Resistant
Antineoplastic Agents
Poly(ADP-ribose) Polymerase Inhibitors

Keywords

Olaparib
Abiraterone Acetate
Prednisone
Prednisolone
Benefit Assessment
NCT03732820
NCT01972217
Prostatic Neoplasms − Castration-Resistant

Contact

Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)

Contact Address: IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851

Contact Email: berichte@iqwig.de

Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.